Page last updated: 2024-12-04

endolysin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lysine-4,4,5,5-d4 : A deuterated compound that is lysne in which the methylene hydrogens at positions 4, 4, 5 and 5 have been replaced by deuterium. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID866
CHEMBL ID28328
CHEBI ID25094
CHEBI ID132486
MeSH IDM0041233

Synonyms (71)

Synonym
lysine, dl-
EN300-34227
AKOS005441647
nsc-620353
dl-lysine
70-54-2
CHEBI:25094 ,
alpha,epsilon-diaminocaproic acid
nsc620353
2,6-diaminohexanoic acid
NCGC00166296-01
NCGC00164527-01
STK387123
(4,4,5,5-(2)h4)lysine
lysine-4,4,5,5-d4
CHEBI:132486
4D4E4503-F6A2-417D-A303-BDCAF08D1EBE
CHEMBL28328
L001250
FT-0693447
FT-0695058
2,6-bis(azanyl)hexanoic acid
A836916
NCGC00164527-02
BBL002414
2,6-diamino-hexanoic acid
h-dl-lys-oh
(+-)-lysine
ai4rt59273 ,
ec 200-740-6
einecs 200-740-6
ccris 8600
(rs)-lysine
unii-ai4rt59273
dl-alpha,epsilon-diaminocaproic acid
(+-)-2,6-diaminohexanoic acid
FT-0625483
FT-0625535
FT-0627942
AM20100662
dl-.alpha.,.epsilon.-diaminocaproic acid
(+/-)-lysine
(+/-)-2,6-diaminohexanoic acid
l-lysine base
Q-201026
CS-7806
mfcd00064433
F8880-9052
mfcd00064432
sr-01000944856
SR-01000944856-1
dl-lysine base
dl-lysine, 98%
dl-lysine, purum, >=95.0% (nt)
endolysin
SY006101
Z57127389
HY-B2236
FT-0772133
Q178430
tetrodotoxincitrate
DTXSID90859004 ,
SB23228
( inverted exclamation marka)-2,6-diaminocaproic acid
lys106
AS-56068
SY006447
SY279831
(+/-)-2,6-diaminocaproic acid
dtxcid00196790
l-lysine-2-15n dihydrochloride

Research Excerpts

Overview

Endolysin is a phage-encoded cell-wall hydrolase which degrades the peptidoglycan layer of the bacterial cell wall. Endolysins prove to be a promising class of antibacterials due to their specificity and less chances of resistance development.

ExcerptReferenceRelevance
"Endolysin is a phage-encoded cell-wall hydrolase which degrades the peptidoglycan layer of the bacterial cell wall. "( Potential Role of the Host-Derived Cell-Wall Binding Domain of Endolysin CD16/50L as a Molecular Anchor in Preservation of Uninfected Clostridioides difficile for New Rounds of Phage Infection.
Chanarat, S; Chankhamhaengdecha, S; Fagan, RP; Janvilisri, T; Nuadthaisong, J; Phetruen, T; Phothichaisri, W, 2022
)
2.4
"Endolysins are a novel class of antibacterials with proven efficacy in combating various bacterial infections, in vitro and in vivo. "( Exploring Endolysin-Loaded Alginate-Chitosan Nanoparticles as Future Remedy for Staphylococcal Infections.
Chhibber, S; Harjai, K; Kaur, J; Kour, A; Panda, JJ, 2020
)
2.4
"Endolysins prove to be a promising class of antibacterials due to their specificity and less chances of resistance development in bacterial pathogens."( Cloning and expression analysis of fused holin-endolysin from RL bacteriophage; Exhibits broad activity against multi drug resistant pathogens.
Basit, A; Qadir, S; Qureshi, S; Rehman, SU, 2021
)
1.6
"Endolysin is a promising antibiotic agent against gram-positive bacteria pathogen, such as Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus aureus."( [Bacteriophage lysins: progress and perspective--a review].
Lu, C; Wang, Y, 2009
)
1.07

Effects

This endolysin has a modular structure with an enzymatically active domain and a cell wall binding domain. It has a lysozyme-like superfamily domain, and its activity was much stronger than that of ly sozyme from chicken egg white.

Endolysins have been proven to have efficient bactericidal activity against pathogens with low incidence of resistance. Endolysin engineering has opened a range of new applications for these proteins from food safety to environmental decontamination.

ExcerptReferenceRelevance
"This endolysin has a modular structure with an enzymatically active domain and a cell wall binding domain."( DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity.
Briers, Y; Gerstmans, H; Lavigne, R; Mesnage, S; Rodríguez-Rubio, L; Thorpe, S, 2016
)
1.16
"The endolysin has a lysozyme-like superfamily domain, and its activity was much stronger than that of lysozyme from chicken egg white."( Characterization of endolysin from a Salmonella Typhimurium-infecting bacteriophage SPN1S.
Kang, DH; Lim, JA; Ryu, S; Shin, H, 2012
)
1.18
"Endolysins have been proposed as a potential antibacterial alternative for aquaculture, especially against Vibrio; the bacterial-agents that most frequently cause disease. "( Biochemical characterization of LysVpKK5 endolysin from a marine vibriophage.
Barraza, A; Cardona-Félix, CS; Loera-Muro, A; Melo-López, FN; Zermeño-Cervantes, LA, 2021
)
2.33
"Endolysins have been studied against a number of drug-resistant pathogens to assess their therapeutic ability."( Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
Chhibber, S; Gondil, VS; Harjai, K, 2020
)
2.72
"Endolysins have been proven to have efficient bactericidal activity against pathogens with low incidence of resistance."( Characterization of a broad-spectrum endolysin LysSP1 encoded by a Salmonella bacteriophage.
Jiang, Y; Li, F; Qu, M; Tan, Z; Wang, L; Xu, D; Yao, L, 2021
)
1.62
"This endolysin has a modular structure with an enzymatically active domain and a cell wall binding domain."( DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity.
Briers, Y; Gerstmans, H; Lavigne, R; Mesnage, S; Rodríguez-Rubio, L; Thorpe, S, 2016
)
1.16
"The endolysin has a lysozyme-like superfamily domain, and its activity was much stronger than that of lysozyme from chicken egg white."( Characterization of endolysin from a Salmonella Typhimurium-infecting bacteriophage SPN1S.
Kang, DH; Lim, JA; Ryu, S; Shin, H, 2012
)
1.18
"Endolysin engineering has opened a range of new applications for these proteins from food safety to environmental decontamination to more effective antimicrobials that are believed refractory to resistance development."( Endolysins as antimicrobials.
Dong, S; Donovan, DM; Klumpp, J; Nelson, DC; Pritchard, DG; Rodriguez-Rubio, L; Schmelcher, M, 2012
)
2.54

Treatment

ExcerptReferenceRelevance
"So endolysin treatment may be a new approach for preventing and controlling of bacteria pathogen."( [Bacteriophage lysins: progress and perspective--a review].
Lu, C; Wang, Y, 2009
)
0.87

Pharmacokinetics

ExcerptReferenceRelevance
" However, its short plasma half-life (20."( A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance.
Fischetti, VA; Moreillon, P; Resch, G, 2011
)
0.37
" An intravenous administration study was conducted in monkeys to obtain pharmacokinetic information on SAL200 and to assess the safety of a short SAL200 dosing period (<1 week)."( Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period.
Han, HY; Jun, SY; Jung, GM; Kang, SH; Lee, JH; Yoon, SJ; Youm, SY, 2016
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" The method was combined with subsequent detection and quantification by the traditional plate-count technique and real-time polymerase chain reaction (PCR)."( Evaluation of paramagnetic beads coated with recombinant Listeria phage endolysin-derived cell-wall-binding domain proteins for separation of Listeria monocytogenes from raw milk in combination with culture-based and real-time polymerase chain reaction-ba
Eichenseher, F; Hein, I; Loessner, MJ; Stessl, B; Wagner, M; Walcher, G, 2010
)
0.59
" Combined with chitosan, XFII could spontaneously lyse Gram-negative bacteria without pretreatment."( Characterization of Salmonella endolysin XFII produced by recombinant Escherichia coli and its application combined with chitosan in lysing Gram-negative bacteria.
Chang, Y; Lu, X; Qi, Q; Yuan, Y; Zhang, Q; Zhang, S, 2022
)
1.01

Bioavailability

ExcerptReferenceRelevance
" However its lower bioavailability under in-vivo conditions limits its applicability as therapeutic agent."( Comprehensive evaluation of chitosan nanoparticle based phage lysin delivery system; a novel approach to counter S. pneumoniae infections.
Chhibber, S; Dube, T; Gondil, VS; Harjai, K; Panda, JJ; Yennamalli, RM, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" An intravenous administration study was conducted in monkeys to obtain pharmacokinetic information on SAL200 and to assess the safety of a short SAL200 dosing period (<1 week)."( Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period.
Han, HY; Jun, SY; Jung, GM; Kang, SH; Lee, JH; Yoon, SJ; Youm, SY, 2016
)
0.72
" In particular, the use of targeted bacteriophage therapy from specialized delivery platforms has shown particular promise owing to the control of delivery location, administration conditions and dosage of the therapeutic cargo."( Recent advances in therapeutic delivery systems of bacteriophage and bacteriophage-encoded endolysins.
Hathaway, H; Jenkins, TA; Milo, S; Sutton, JM, 2017
)
0.68
"6%), which seems to be promising causative agents for the development of finished dosage form."( Determination of Bactericidal Activity Spectrum of Recombinant Endolysins of ECD7, Am24, Ap22, Si3, and St11 Bacteriophages.
Aleshkin, AV; Antonova, NP; Anurova, MN; Bakhrushina, EO; Bochkareva, SS; Gushchin, VA; Kaminskii, VV; Karaulov, AV; Kiseleva, IA; Laishevtsev, AI; Mekhtiev, ER; Rubalskii, EO; Vasina, DV; Vorob'ev, AM; Zul'karneev, ER, 2021
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Daphnia magna metaboliteA Daphnia metabolite produced by the species Daphnia magna.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
alpha-amino acidAn amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group.
diamino acidAny amino acid carrying two amino groups.
polar amino acidAny amino acid whose side chain is capable of forming one or more hydrogen bonds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
22q11.2 copy number variation syndrome228
Biotin metabolism, including IMDs912
Amino acid transport defects (IEMs)925
Cerebral organic acidurias, including diseases527

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.14130.003245.467312,589.2998AID2517
lamin isoform A-delta10Homo sapiens (human)Potency28.18380.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (468)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (2.14)18.7374
1990's14 (2.99)18.2507
2000's59 (12.61)29.6817
2010's250 (53.42)24.3611
2020's135 (28.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.14 (24.57)
Research Supply Index6.17 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index87.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.63%)5.53%
Reviews46 (9.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other424 (89.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]